Literature DB >> 33394057

A hesitated approach: primary radiotherapy for keloids-a case series.

Sezin Yuce Sari1, Melek Tugce Yilmaz1, Gozde Yazici2, Hakan Uzun3, Fazli Yagiz Yedekci1, Gokhan Ozyigit1.   

Abstract

PURPOSE: To assess the efficacy and toxicity of hypofractionated radiotherapy (RT) alone in treatment-resistant symptomatic keloids.
METHODS: Six patients with a total of 13 inoperable large keloid lesions and no response to previous treatments were admitted to our department between 2017 and 2019. All patients were examined for detailed wound localization, size, contour, and color assessment, and for objective and subjective symptoms. Response to treatment was graded as "complete remission" in case of full symptomatic relief and >75% decrease in lesion size, as "partial remission" in case of partial symptomatic relief and 25-75% decrease in lesion size, and as "stable disease" in case of no symptomatic relief or <25% decrease in lesion size. Patients were followed up monthly for the first 3 months and every 3 months thereafter by physical examination.
RESULTS: A total dose of 37.5 Gy external RT in five fractions was prescribed by 6‑MeV electrons in 4 patients and 6‑MV photons in 2 patients. Complete response was obtained in all patients at the 6‑month control. All patients were satisfied with cosmetic results at their last control. Grade 2 dermatitis developed in all patients during the second week of RT but resolved completely in all after 6 months following the end of RT.
CONCLUSION: In keloids that are unresponsive to standard treatment, hypofractionated RT using a total dose of 37.5 Gy in five fractions is feasible.
© 2020. Springer-Verlag GmbH, DE part of Springer Nature.

Entities:  

Keywords:  Definitive radiotherapy; Hypofractionated radiotherapy; Keloid; Keloid scar; Radiotherapy

Mesh:

Year:  2021        PMID: 33394057     DOI: 10.1007/s00066-020-01736-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  32 in total

Review 1.  International clinical recommendations on scar management.

Authors:  Thomas A Mustoe; Rodney D Cooter; Michael H Gold; F D Richard Hobbs; Albert-Adrien Ramelet; Peter G Shakespeare; Maurizio Stella; Luc Téot; Fiona M Wood; Ulrich E Ziegler
Journal:  Plast Reconstr Surg       Date:  2002-08       Impact factor: 4.730

2.  Histopathological differential diagnosis of keloid and hypertrophic scar.

Authors:  Julia Yu-Yun Lee; Chao-Chun Yang; Sheau-Chiou Chao; Tak-Wah Wong
Journal:  Am J Dermatopathol       Date:  2004-10       Impact factor: 1.533

Review 3.  Biologically effective doses of postoperative radiotherapy in the prevention of keloids. Dose-effect relationship.

Authors:  Henk B Kal; Ronald E Veen
Journal:  Strahlenther Onkol       Date:  2005-11       Impact factor: 3.621

4.  Functional implications of the IL-6 signaling pathway in keloid pathogenesis.

Authors:  Mohammad Ghazizadeh; Mamiko Tosa; Hajime Shimizu; Hiko Hyakusoku; Oichi Kawanami
Journal:  J Invest Dermatol       Date:  2006-10-05       Impact factor: 8.551

5.  Combined surgical excision and radiation therapy for keloid treatment.

Authors:  Sadanori Akita; Kozo Akino; Aya Yakabe; Toshifumi Imaizumi; Katsumi Tanaka; Kuniaki Anraku; Hiroki Yano; Akiyoshi Hirano
Journal:  J Craniofac Surg       Date:  2007-09       Impact factor: 1.046

6.  Postoperative irradiation in the prevention of keloids.

Authors:  D S Levy; M M Salter; R E Roth
Journal:  AJR Am J Roentgenol       Date:  1976-09       Impact factor: 3.959

7.  Lymphocyte-mediated activation of fibroblast proliferation and collagen production.

Authors:  S M Wahl; L M Wahl; J B McCarthy
Journal:  J Immunol       Date:  1978-09       Impact factor: 5.422

Review 8.  Is radiation therapy for keloids acceptable? The risk of radiation-induced carcinogenesis.

Authors:  Rei Ogawa; Sumiko Yoshitatsu; Ken Yoshida; Tsuguhiro Miyashita
Journal:  Plast Reconstr Surg       Date:  2009-10       Impact factor: 4.730

9.  Are keloid and hypertrophic scar different forms of the same disorder? A fibroproliferative skin disorder hypothesis based on keloid findings.

Authors:  Chenyu Huang; Satoshi Akaishi; Hiko Hyakusoku; Rei Ogawa
Journal:  Int Wound J       Date:  2012-11-22       Impact factor: 3.315

Review 10.  TGF-beta: a fibrotic factor in wound scarring and a potential target for anti-scarring gene therapy.

Authors:  W Liu; D R Wang; Y L Cao
Journal:  Curr Gene Ther       Date:  2004-03       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.